Respiratory tract infection, digestive tract infection, trauma and postoperative infection are common, but their complications and related potential risks cannot be ignored in clinical practice. In recent years, with the increasing research, the application of infection markers to auxiliary diagnosis infection has attached more and more attentions, such as procalcitonin (PCT), C reactive protein (CRP), serum amyloid A (SAA), white blood cells (WBC), etc. Today, we are going to share something about PCT.

Precision medicine is a medical model based on individual-specific data such as genetics, biomarkers, and environmental factors, combined with advanced scientific and technological means (such as gene sequencing, biochip technology, data mining, artificial intelligence, etc.) for the prevention, diagnosis, treatment, and monitoring of diseases to be personalized, precise and customized. Compared with the traditional patient treatment mode, it pays more attention to the influence of individual factors, provides more accurate, more effective, and safer treatment programs, and has the advantages of strong guidance, high effectiveness, and high resource utilization rate.

With the progress of medical technology and the development of social economics, the average life expectancy of human beings has been significantly improved. However, this kind of human social progress has brought a huge challenge -- population aging. At present, the proportion of the elderly population in the world is increasing rapidly. According to the World Social Report 2023 released by the United Nations on January 12th, the global population aged 65 and above is 761 million in 2021, and this number will increase to 1.6 billion by 2050. The population aged 80 and above is growing faster.

Point-of-care testing (POCT) is the rapid testing of biological samples (such as blood, urine, saliva, breath gas, etc.) at the patient's side, using simple instruments or reagents, and results can be obtained within minutes to hours. The test can help physicians make timely diagnosis and treatment plans, and provide important information to improve treatment outcomes in an emergency setting.

According to the latest HSC Common List published on October 17, 2022, the SARS-CoV-2 Antigen Rapid Test produced by Wizbiotech has been listed in HSC Common List Class A.